March 19 (Reuters) - AstraZeneca ( AZN ) said on Tuesday
it has agreed to buy clinical-stage biopharmaceutical company
Fusion Pharmaceuticals Inc ( FUSN ) for about $2 billion in
cash.
The drugmaker will pay $21 per Fusion share plus a
non-transferable contingent value right of $3 per share.